drugset / Trial / NCT01519245

Topical Application of Tranexamic Acid to Reduce Post-operative Bleeding in Coronary Artery Bypass Surgery

NCT01519245 ↗

RandomizedParallel-groupQuadruple-blindPrevention

Summary

The goal of this project is to determine whether the use of tranexamic acid, a clot-promoting drug, applied topically over the heart in coronary artery bypass graft surgery (CABG) will reduce post operative blood loss. The investigators' hypothesis is that the use of a tranexamic acid-containing cardiac bath prior to chest closure will result in a statistically significant reduction in blood loss and transfusion requirements in patients who undergo CABG.

Timeline

Start
2011-12
Primary completion
2012-04
Completion
2012-06

Outcome

Met primary endpoint

registry MEAN Trial Drug: 632 (Standard Deviation 265) mL MEAN Placebo: 789 (Standard Deviation 216) mL NCT01519245 ↗

registry analysis (superiority or other test); Trial Drug vs Placebo; p = 0.0493; t-test, 2 sided NCT01519245 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Tranexamic Acid Small molecule 2 g Topical